Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Raises Price Target to $9.5
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Craig Hettenbach maintains an Equal-Weight rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $7 to $9.5.
June 10, 2024 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Craig Hettenbach maintains an Equal-Weight rating on GoodRx Holdings and raises the price target from $7 to $9.5.
The raised price target from $7 to $9.5 by a reputable analyst at Morgan Stanley is likely to have a positive short-term impact on GoodRx Holdings' stock price. The Equal-Weight rating suggests a neutral stance, but the increased price target indicates improved expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100